ev3 Inc. Product Pipeline Analysis

Publication Date	August 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	72
ISBN Number	not applicable
Product Code	GMD04751

Price

£400.00
approximately: $747 | €507

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a ev3 Inc.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reasons to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1 List of Tables
- 1.2 List of Figures
2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
- 2.4 Industry Outlook Cardiovascular Devices
3 Business Description
- 3.1 Business Overview
- 3.2 Neurovascular Segment
  - 3.2.1 Overview
  - 3.2.2 Financials
  - 3.2.3 Market View
  - 3.2.4 Key Strategies
- 3.3 Peripheral Vascular Segment
  - 3.3.1 Overview
  - 3.3.2 Financials
  - 3.3.3 Market View
  - 3.3.4 Key Strategies
- 3.4 Major Products and Services
  - 3.4.1 Overview
4 History
5 Business Strategy
- 5.1 Mission Statement
- 5.2 Strategy
6 Value Chain Analysis
- 6.1 Manufacturing
  - 6.1.1 In House Manufacturing
- 6.2 Product Development
  - 6.2.1 Regulatory Approvals
  - 6.2.2 Clinical Trials
  - 6.2.3 Research and Development
- 6.3 Sales and Marketing
  - 6.3.1 Partnerships and Alliances
  - 6.3.2 Licensing Agreements
7 Competitors
8 Share Holding Structure
9 Key Employees
10 Key Employee Biographies
11 Company Statement
12 Locations And Subsidiaries
- 12.1 Head Office
- 12.2 Other Locations & Subsidiaries
13 Recent Developments
- 13.1 Financial Announcements
  - 13.1.1 Jul 28, 2008: ev3 Reports 2Q 2008 Results
  - 13.1.2 May 02, 2008: ev3 Reports Q1 2008 Results
  - 13.1.3 Apr 18, 2008: ev3 To Declare Q1 2008 Results
  - 13.1.4 Feb 22, 2008: ev3 Reports Q4 2007 Results
  - 13.1.5 Feb 08, 2008: ev3 To Declare Q4 And 2007 Results
  - 13.1.6 Jan 07, 2008: ev3 Reports Preliminary Q4 2007 Results and Revised 2008 Guidance
  - 13.1.7 Oct 31, 2007: ev3 Reports Q3 2007 Results
  - 13.1.8 Jul 22, 2007: ev3 Reports Q2 2007 Results
  - 13.1.9 Apr 27, 2007: ev3 Reports Q1 2007 Results
  - 13.1.10 Feb 20, 2007: ev3 Reports Year-End 2006 Results
  - 13.1.11 Oct 20, 2006: ev3 Reports Q3 2006 Results
  - 13.1.12 Jul 28, 2006: ev3 Reports Q2 2006 Results
- 13.2 Corporate Communications
  - 13.2.1 Aug 04, 2008: ev3 Appoints New Board Member
  - 13.2.2 Jul 21, 2008: ev3 Announces Management Changes
  - 13.2.3 Apr 07, 2008: ev3 Announces Management Changes
  - 13.2.4 Feb 08, 2008: ev3 Chief Scientist And Board Member Resigns
  - 13.2.5 Feb 27, 2007: ev3 Appoints New Director
- 13.3 Product News
  - 13.3.1 Dec 18, 2007: ev3 Introduces New Enhanced Offering For The Treatment Of Peripheral Artery Disease
  - 13.3.2 Dec 18, 2007: ev3 Introduces New Enhanced Offerings For The Treatment Of Peripheral Artery Disease
  - 13.3.3 Jun 04, 2007: ev3 Receives Conditional IDE Approval To Study Use Of Protg EverFlex Self-Expanding Stent System In The Treatment Of Peripheral Artery Disease
  - 13.3.4 Feb 15, 2006: SilverHawk Plaque Excision Shown To Minimize The Amputation Rate In Multi-Center Publication Of Patients With Critical Limb Ischemia
  - 13.3.5 Apr 11, 2003: Early Results Show PLAATO Device Safe And Feasible For Stroke Prevention In Patients With Atrial Fibrillation
- 13.4 Product Approvals
  - 13.4.1 Jun 04, 2007: ev3 Receives Conditional IDE Approval To Study Use Of Protg EverFlex Self-Expanding Stent System In The Treatment Of Peripheral Artery Disease
- 13.5 Clinical Trials
  - 13.5.1 Feb 15, 2006: SilverHawk Plaque Excision Shown To Minimize The Amputation Rate In Multi-Center Publication Of Patients With Critical Limb Ischemia
  - 13.5.2 Apr 11, 2003: Early Results Show PLAATO Device Safe And Feasible For Stroke Prevention In Patients With Atrial Fibrillation
14 ev3 Inc. Pipeline Products
- 14.1 ev3 Inc. Product Pipeline Analysis
  - 14.1.1 ev3 Inc. Pipeline Products By Equipment Type
  - 14.1.2 ev3 Inc. Pipeline Products By Development Stage
  - 14.1.3 ev3 Inc. Pipeline Products By Therapy Area
  - 14.1.4 ev3 Inc. Pipeline Products By Clinical Trials
  - 14.1.5 ev3 Inc. Pipeline Products By News Summary
- 14.2 PLAATO
  - 14.2.1 Product Description
  - 14.2.2 Product Status
  - 14.2.3 Clinical Trials
  - 14.2.4 Product Milestone
- 14.3 PROTEGE EverFlex Stent
  - 14.3.1 Product Description
  - 14.3.2 Product Status
  - 14.3.3 Clinical Trials
  - 14.3.4 Product Milestone
- 14.4 RockHawk Plaque Excision System
  - 14.4.1 Product Description
  - 14.4.2 Product Status
  - 14.4.3 Clinical Trials
  - 14.4.4 Product Patent Details
- 14.5 RockHawk for endovascular use
  - 14.5.1 Product Description
  - 14.5.2 Product Status
- 14.6 Gen II SilverHawk
  - 14.6.1 Product Description
  - 14.6.2 Product Status
  - 14.6.3 Clinical Trials
  - 14.6.4 Product Patent Details
- 14.7 Spider Fx
  - 14.7.1 Product Description
  - 14.7.2 Product Status
  - 14.7.3 Clinical Trials
- 14.8 Silver Hawk Peripheral Calcium Tip Plaque Excision System with Spider X Embolic Protection Device
  - 14.8.1 Product Description
  - 14.8.2 Product Status
- 14.9 Solitaire Stent
  - 14.9.1 Product Description
  - 14.9.2 Product Status
15 Appendix
- 15.1 Methodology
  - 15.1.1 Coverage
  - 15.1.2 Secondary Research
  - 15.1.3 Primary Research
  - 15.1.4 Expert Panel Validation
- 15.2 Contact Us
- 15.3 About Global Markets Direct
- 15.4 Disclaimer
1 List of Tables
- Table 1: ev3 Inc.,Key Facts, 2007
- Table 2: ev3 Inc., Share Holding Structure
- Table 3: ev3 Inc., Key Employees, 2007
- Table 4: ev3 Inc., Other Locations
- Table 5: ev3 Inc., Subsidiaries
- Table 6: ev3 Inc. Pipeline Products by Equipment Type
- Table 7: ev3 Inc. Pipeline Products By Development Stage
- Table 8: ev3 Inc. Pipeline Products By Therapy Area
- Table 9: ev3 Inc. Pipeline Products By Clinical Trials
- Table 10: ev3 Inc. Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: ev3 Inc., Value Chain Analysis
- Figure 2: ev3 Inc. Pipeline Products By Equipment Type
- Figure 3: ev3 Inc. Pipeline Products By Equipment Type
- Figure 4: ev3 Inc. Pipeline Products By Development Stage
- Figure 5: Global Markets Direct Methodology